⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CING News
Cingulate Inc. Common Stock
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
CING
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
globenewswire.com
CING
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
globenewswire.com
CING
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
globenewswire.com
CING
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date
globenewswire.com
CING